(RTTNews) – Taiwan pharmaceutical specialty pharmaceutical company Taiwan Liposome Co.Ltd. (TLC) announced Friday that it will submit an application for a new experimental drug (IND) to the Taiwan Food and Drug Administration (TFDA) for the suspension of hydroxychloroquine inhalation. liposomes coronavirus disease TLC19 (COVID-19).
TLC19 uses existing TLC liposome generation to encapsulate approximately 1/100 of the oral dose of HCQ in inhalable formulas for direct deposition in airlines and lungs.
A recent manuscript showed that in doses, increased exposure (approximately 30 times) and half-life (approximately 2.5 times) in the lungs compared to oral HCQ. TLC19 can achieve an antiviral effect with a small dose compared to oral HCQ while reducing blood and heart exposure, giving TLC19 the chance to treat COVID-19.
TLC is running with MicroBase Technology Corp., which specializes in the progression of inhalation devices for the respiratory disease remedy, to drive the progression of TLC19 inhalation suspension formulas.
The company said a Phase I clinical trial will be launched and will recruit healthy volunteers in Taiwan to gather knowledge on pharmacokinetics and protection on new liposome formulas with the new inhalation route.
Phase II/III clinical trials are expected to be established in the United States and the countries most affected by the pandemic.